Protagen Protein Services, BioAnalytix, and GeneWerk Combine to Form New CRO, ProtaGene

Following their July 2021 merger, Protagen Protein Services, BioAnalytix, and GeneWerk announced on Jan. 12, 2022 that their unified operations and re-branded name is ProtaGene, a contract research organization for the biopharmaceutical and cell and gene therapy industries.

The three legacy companies' combined synergy provides advanced, integrated, and complete protein and gene analytic services for biological therapeutics and cell and gene therapy platforms. ProtaGene provides services from discovery to commercialization.

Previously, Protagen Protein Services and BioAnalytix merged in April 2019, and GeneWerk, which specializes in vector safety, integration site analysis, and bioinformatics, was combined with the group in 2021.

"We are very excited to launch ProtaGene. The track record and reputation of the three legacy entities are individually impressive, and their combination into a single, globally integrated business delivers significant compounded value for our sponsors," said Martin Blüggel, CEO of ProtaGene and the founder of Protagen Protein Services, in a company press release.

"By combining our capabilities, platforms and knowledge, we can now provide our US-based biopharmaceutical and gene therapy customers advanced access to the broadest analytical offering from discovery to market, from a single vendor relationship," said Kirtland Poss, CEO-US of ProtaGene and the founder of BioAnalytix, in the press release.

"Our unique experience in gene analytics—especially integration site analysis, vector purity, vector copy numbers, and bioinformatics analysis for preclinical development and clinical trials—will support many innovators in taking breakthrough therapies to the clinic," added Annette Deichmann, senior vice-president of Cell and Gene Therapy at ProtaGene and the co-founder of GeneWerk, in the press release.

Source: ProtaGene